DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Trims Holdings in Moderna, Inc. (NASDAQ:MRNA)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 12.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,894 shares of the company’s stock after selling 2,045 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in Moderna were worth $619,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the last quarter. Compass Planning Associates Inc acquired a new position in Moderna in the fourth quarter worth about $37,000. Crowley Wealth Management Inc. bought a new stake in Moderna in the fourth quarter valued at about $41,000. Finally, Itau Unibanco Holding S.A. raised its stake in Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock valued at $42,000 after buying an additional 343 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MRNA shares. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Thursday, April 17th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Evercore ISI lowered their target price on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. UBS Group reduced their price target on shares of Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Finally, Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $53.95.

Moderna Stock Down 0.5%

Shares of MRNA opened at $24.25 on Monday. The firm has a market capitalization of $9.38 billion, a PE ratio of -2.61 and a beta of 1.99. The firm has a 50-day moving average price of $28.89 and a 200 day moving average price of $36.34. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. During the same period last year, the firm posted ($3.07) earnings per share. The business’s revenue was down 35.3% on a year-over-year basis. On average, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.